Cellutions, a startup focused on medical devices and procedures to treat cellulite, has closed on $7 million in new funding, according to VentureWire.

The company, which was formed in 2004, landed Versant Ventures as a new investor. Existing investors Carlyle Venture partners and SV Life Sciences also participated.

Cellutions raised a $5.6 million Series A round for proof of concept and feasibility studies.

According to the firm’s Web site, cellulite affects 90 percent of post-adolescent females. Its proposed technology and procedure would be performed on an outpatient basis in what the company calls a “lunchtime” treatment.